Omeros Corporation stock falls 3.28 percent while analysts target USD 22.00

Published on 09/28/2026 at 17:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omeros Corporation stock now faces a USD 22.00 Cantor Fitzgerald target after a September 22 upgrade. Q2 revenue reached USD 28.53 million versus USD 12.69 million consensus.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation (ISIN US6821431029) stock was trading at USD 19.42 on Nasdaq at 11:51 a.m. ET on September 28, 2026, down 3.28 percent from the prior close of USD 20.08. The latest catalyst remains the commercial response to YARTEMLEA, which helped the company beat second-quarter expectations and prompted a new analyst upgrade.

YARTEMLEA lifts quarterly figures

Omeros reported Q2 2026 revenue of USD 28.53 million, compared with analysts' consensus of USD 12.69 million, according to MarketBeat in its September 22, 2026 report. Quarterly EPS was USD 0.02 against an expected loss of USD 0.27, giving investors a sharper earnings comparison than the share price alone suggests.

The result followed the launch of YARTEMLEA, Omeros' approved treatment for thrombotic microangiopathy associated with hematopoietic stem-cell transplantation. The commercial product is part of a broader biotechnology portfolio focused on complement-mediated diseases, according to the company's investor-relations profile.

Cantor sets USD 22.00 target

Investing.com reported on September 22, 2026 that Cantor Fitzgerald raised Omeros from Neutral to Overweight and assigned a USD 22.00 price target. At the September 28 price of USD 19.42, that target lies 13.29 percent above the stock.

Cantor's case centers on stronger-than-expected YARTEMLEA performance and additional physician research after the second-quarter report. The assessment gives the market a concrete benchmark, but the current session's 3.28 percent decline shows that favorable operating data have not removed short-term trading risk.

Insider sales add a counterpoint

MarketBeat said insiders sold 95,906 shares worth USD 1.78 million during the 90 days covered by its September 22 report. A separate September 25 filing report from Investing.com said Omeros finance executive David J. Borges sold 20,000 shares at USD 20.95 on September 22 and September 23, 2026.

That selling activity contrasts with the improving quarterly revenue profile and leaves YARTEMLEA adoption as the central operating measure for the next update. The stock's 52-week range is USD 4.06 to USD 21.24, putting the current quote USD 1.82 below the yearly high.

OMER trades below its yearly high

OMER was last at USD 19.42 on Nasdaq on September 28, 2026 at 11:51 a.m. ET, with a market capitalization of USD 1.4 billion and volume of 317,493 shares. The share price remains above its 52-week low, while the USD 22.00 analyst target keeps the next valuation checkpoint clearly defined.